IP Library Granted Patent US 10,328,180
Granted Patent B2
US 10,328,180 · App. 15/173,850 · Granted Jun 25, 2019

Hyaluronic acid-based gels including lidocaine

Inventor: Pierre F. Lebreton (Annecy, FR)
Assignee: Allergan Industrie, S.A.S.
A61L27/52A61K8/42A61K8/735A61K9/0021A61K31/167A61K31/728A61K47/36A61L27/20A61L27/54A61Q19/08A61L2300/402A61L2300/602A61L2400/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,328,180
App. No.
15/173,850
Granted
Jun 25, 2019
Kind
B2
Abstract

Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Claims (10)

1. A sterile, stable injectable soft tissue filler composition comprising:

a mixture of soluble form hyaluronic acid (HA), crosslinked HA, and lidocaine in an amount effective to mitigate pain upon injection of the composition, the crosslinked HA being crosslinked with 1,4-butanediol diglycidyl ether (BDDE); and

the composition having a HA concentration of about 22 mg/ml.

2. The soft tissue filler composition of claim 1 wherein the soluble form is present in the filler composition in an amount greater than 10% by weight of the composition.

3. The soft tissue filler composition of claim 1 wherein the soluble form is present in the filler composition in an amount greater than 15% by weight of the composition.

4. The soft tissue filler composition of claim 1 wherein the soluble form is present in the filler composition in an amount greater than 20% by weight of the composition.

5. The soft tissue filler composition claim 1 wherein the crosslinked HA has a degree of crosslinking of less than about 6%.

6. The soft tissue filler composition claim 5 wherein the crosslinked HA has a degree of crosslinking of less than about 5%.

7. The soft tissue filler composition of claim 1 wherein the crosslinked HA has a degree of crosslinking of about 2%.

8. The soft tissue filler composition of claim 5 wherein the lidocaine is at a concentration of between about 0.1% and 5% by weight of the composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2016
From: LEBRETON, PIERRE F.
To: ALLERGAN INDUSTRIE, S.A.S.
Reel/Frame 038813/0988 →
Continuity (6)
Continuation 13891052 · May 9, 2013
Continuation 12393768 · Feb 26, 2009
Provisional Application 61085956 · Aug 4, 2008
Provisional Application 61087934 · Aug 11, 2008
Provisional Application 61096278 · Sep 11, 2008
Related Publication 20160279296A1 · Sep 29, 2016